Relay Therapeutics, Inc. (RLAY) Stock Analysis
Healthcare · Biotechnology
Sell if holding. Engine safety override at $11.81: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality.
Relay Therapeutics is a clinical-stage precision medicine company developing small molecule therapies using its Dynamo Motion-Based Drug Design platform. Lead candidate zovegalisib (RLY-2608), the first allosteric pan-mutant PI3Kα inhibitor, entered Phase 3 (ReDiscover-2 Trial)... Read more
Sell if holding. Engine safety override at $11.81: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 4.9/10, moderate confidence.
Passes 6/7 gates (favorable risk/reward ratio, clean insider activity, no SEC red flags, earnings proximity 79d clear, semi cycle peak clear, materials cycle peak clear). Fails on weak momentum. Suitability: aggressive.
Recent Developments — Relay Therapeutics, Inc.
Latest news
- Barclays Maintains Overweight on Relay Therapeutics, Raises Price Target to $27 — benzinga May 20, 2026 positive
- Citizens Maintains Market Outperform on Relay Therapeutics, Raises Price Target to $21 — benzinga May 20, 2026 positive
- Lowe's, ZTO Express, Viavi Solutions And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session — benzinga May 20, 2026 negative
- Relay Therapeutics Launches $175M Public Stock Offering — benzinga May 19, 2026 neutral
- Raymond James Maintains Strong Buy on Relay Therapeutics, Raises Price Target to $26 — benzinga May 19, 2026 positive
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- HIGHpipelinezovegalisib (RLY-2608)10-K Item 1: 'We are advancing a pipeline of medicine candidates to address targets in precision oncology and genetic disease, including zovegalisib (RLY-2608), our lead product candidate'
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
3 floor-breakers·1 ceiling hit
Quality below the gate floor. Component breakdown shows what dragged the score down.static
Volatile — 6.9% daily ATR makes tight stops impractical. Position-size conservatively.static
Ranks in the bottom of its industry peers on the composite signal. Better names in the same sector exist.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. Engine safety override at $11.81: Quality below floor (1.2 < 4.0) triggers a hard block regardless of the otherwise-positive setup — overall score 4.9/10 and A.R:R 3.9:1 is above the 1.5:1 BUY gate. Specifically: High short interest: 17%; Below-average business quality. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $11.28. Score 4.9/10, moderate confidence.
Take-profit target: $18.49 (+53.2% upside). Prior stop was $11.28. Stop-loss: $11.28.
Concentration risk — Pipeline: zovegalisib (RLY-2608); Quality below floor (1.2 < 4.0).
Relay Therapeutics, Inc. trades at a P/E of N/A (forward -7.0). TrendMatrix value score: 9.0/10. Verdict: Sell.
19 analysts cover RLAY with a consensus score of 4.3/5. Average price target: $21.
What does Relay Therapeutics, Inc. do?Relay Therapeutics is a clinical-stage precision medicine company developing small molecule therapies using its Dynamo...
Relay Therapeutics is a clinical-stage precision medicine company developing small molecule therapies using its Dynamo Motion-Based Drug Design platform. Lead candidate zovegalisib (RLY-2608), the first allosteric pan-mutant PI3Kα inhibitor, entered Phase 3 (ReDiscover-2 Trial) in Q2 2025 for HR+/HER2- PI3Kα-mutated breast cancer; FDA Breakthrough Therapy designation granted February 2026.